These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19950162)

  • 1. Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors.
    Skobridis K; Kinigopoulou M; Theodorou V; Giannousi E; Russell A; Chauhan R; Sala R; Brownlow N; Kiriakidis S; Domin J; Tzakos AG; Dibb NJ
    ChemMedChem; 2010 Jan; 5(1):130-9. PubMed ID: 19950162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
    Taylor JR; Brownlow N; Domin J; Dibb NJ
    Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells.
    Chang S; Yin SL; Wang J; Jing YK; Dong JH
    Molecules; 2009 Oct; 14(10):4166-79. PubMed ID: 19924055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
    Dewar AL; Cambareri AC; Zannettino AC; Miller BL; Doherty KV; Hughes TP; Lyons AB
    Blood; 2005 Apr; 105(8):3127-32. PubMed ID: 15637141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level.
    Peng Z; Maxwell DS; Sun D; Bhanu Prasad BA; Pal A; Wang S; Balatoni J; Ghosh P; Lim ST; Volgin A; Shavrin A; Alauddin MM; Gelovani JG; Bornmann WG
    Bioorg Med Chem; 2014 Jan; 22(1):623-32. PubMed ID: 24280068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
    Glekas AP; Pillarsetty NK; Punzalan B; Khan N; Smith-Jones P; Larson SM
    J Nucl Med; 2011 Aug; 52(8):1301-7. PubMed ID: 21764785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis.
    Nurmio M; Kallio J; Toppari J; Jahnukainen K
    Reprod Toxicol; 2008 Aug; 25(4):442-6. PubMed ID: 18472395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
    Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
    Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel Bcr-Abl
    Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
    Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors.
    Dewar AL; Domaschenz RM; Doherty KV; Hughes TP; Lyons AB
    Leukemia; 2003 Sep; 17(9):1713-21. PubMed ID: 12970769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of c-fms by imatinib: expanding the spectrum of treatment.
    Dewar AL; Zannettino AC; Hughes TP; Lyons AB
    Cell Cycle; 2005 Jul; 4(7):851-3. PubMed ID: 15917650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
    Fernández A; Sanguino A; Peng Z; Ozturk E; Chen J; Crespo A; Wulf S; Shavrin A; Qin C; Ma J; Trent J; Lin Y; Han HD; Mangala LS; Bankson JA; Gelovani J; Samarel A; Bornmann W; Sood AK; Lopez-Berestein G
    J Clin Invest; 2007 Dec; 117(12):4044-54. PubMed ID: 18060038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of imatinib (STI571).
    Buchdunger E; O'Reilly T; Wood J
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.